Supplementary figures and table for Vaccination Coverage by Age 24 Months Among Children Born in 2015 and 2016 – National Immunization Survey-Child, United States, 2016-2018

At a glance

Supplementary vaccination coverage data from the NIS-Child are included below. The table shows vaccination coverage comparison estimates for two survey years. The figures show trends of estimated vaccination coverage and estimated percentages of children with no vaccinations.

Supplementary Table 1

Vaccination coverage estimates for bridging cohort,* National Immunization Survey-Child, United States, 2017-2018

Children Born January 2015 through May 2016
Survey Year 2017 Survey Year 2018 Difference (2018 – 2017) P-value for Test of Difference=0
Vaccine Estimate SE Estimate SE Estimate SE
≥3 DTaP by 19 months 93.2 0.57 93.2 0.45 0.0 0.73 0.963
≥4 DTaP by 19 months 71.4 1.14 70.1 1.05 -1.2 1.55 0.423
≥3 Poliovirus by 19 months 91.1 0.75 91.4 0.53 0.3 0.92 0.756
≥1 MMR by 19 months§ 87.1 0.82 88.1 0.67 1.0 1.06 0.355
Hib primary series by 19 months 92.9 0.54 92.0 0.56 -0.9 0.78 0.262
Hib full series by 19 months 75.6 0.99 74.6 0.99 -0.9 1.40 0.505
HepB birth dose** 75.3 1.16 74.4 1.03 -0.9 1.55 0.555
≥3 HepB by 19 months 90.9 0.62 90.4 0.68 -0.5 0.92 0.595
≥1 VAR by 19 months§ 87.0 0.77 87.1 0.69 0.0 1.04 0.977
≥3 PCV by 19 months 91.7 0.65 91.4 0.59 -0.3 0.88 0.703
≥4 PCV by 19 months 78.2 0.97 77.0 0.97 -1.2 1.37 0.383
≥1 HepA by 19 months 80.9 0.85 80.4 0.86 -0.5 1.21 0.663
≥2 HepA by 19 months 23.9 0.98 25.6 1.00 1.7 1.40 0.234
Rotavirus by 19 months†† 74.5 1.15 74.1 1.05 -0.4 1.55 0.806
Combined 7-vaccine series by 19 months§§ 60.4 1.21 59.7 1.15 -0.7 1.67 0.682
No vaccinations 1.0 0.12 1.1 0.16 0.1 0.20 0.521

Abbreviations: DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; SE = standard error; VAR = varicella vaccine.

* The bridging birth cohort used for this analysis includes children born between January 2015 and May 2016.

Includes children who may have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.

§ Includes children who may have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.

Hib primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.

** One dose HepB administered from birth through age 3 days.

†† Includes ≥2 doses of Rotarix monovalent rotavirus vaccine (RV1), or ≥3 doses of RotaTeq pentavalent rotavirus vaccine (RV5). The maximum age for the final rotavirus dose is 8 months, 0 days.

§§ The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of VAR, and ≥4 doses of PCV.

Supplementary Figure 1

Estimated Vaccination Coverage by Age 24 Months,* by Birth Year, National Immunization Survey-Child 2012-2018, United States

SUPPLEMENTARY FIGURE 1. Estimated Vaccination Coverage by Age 24 Months,* by Birth Year,† National Immunization Survey-Child 2012-2018, United States
Vaccination coverage was stable by single birth year from 2011 through 2016 except for an increase in ≥2 doses of HepA by age 35 months from 71.1% (2011) to 76.6% (2016).

Abbreviations: DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; VAR = varicella vaccine.

* Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by 35 months. For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (35 months for ≥2 HepA doses).

Children born in 2011 are included in survey years 2012, 2013, and 2014; children born in 2012 are included in survey years 2013, 2014, and 2015; children born in 2013 are included in survey years 2014, 2015, and 2016, children born in 2014 are included in survey years 2015, 2016, and 2017; children born in 2015 are included in survey years 2016, 2017, and 2018; children born in 2016 are included in survey years 2017 and 2018 (data from survey year 2019 are not yet available). Linear relationship between year of birth and vaccination status was estimated based on weighted linear regression analysis using the inverse of the estimated variance of each point estimate to construct the weights. Estimated percentage point change over one birth year (95% confidence interval): ≥4 DTaP -0.2 (-0.6-0.2) ; ≥3 Poliovirus 0.0 (-0.6-0.5); ≥1 MMR 0.0 (-0.3-0.3); Hib full series -0.1 (-0.5-0.3); HepB birth dose 0.4 (-0.8-1.6); ≥3 HepB 0.1 (-0.6-0.7) ; ≥1 Varicella 0.1 (-0.3-0.4) ; ≥4 PCV -0.1(-0.6-0.4); ≥2 HepA (35 mo) 1.1 (0.4-1.8); Rotavirus 0.6 (0.0-1.2); ≥2 Influenza 0.7 (-0.4-1.8); 7-vaccine series 0.1 (-0.3-0.4).

§ Includes children who may have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.

¶ Includes children who may have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.

** Hib full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.

†† One dose HepB administered from birth through age 3 days.

§§ Includes ≥2 doses of Rotarix monovalent rotavirus vaccine (RV1), or ≥3 doses of RotaTeq pentavalent rotavirus vaccine (RV5). The maximum age for the final rotavirus dose is 8 months, 0 days.

¶¶ Doses must be at least 24 days apart (four weeks with a four-day grace period).

*** The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of VAR, and ≥4 doses of PCV.

Supplementary Figure 2

Estimated percentage of children who received no vaccinations by age 24 months,* by birth year–National Immunization Survey-Child 2012-2018, United States

SUPPLEMENTARY FIGURE 2. Estimated percentage of children who received no vaccinations by age 24 months,* by birth year†--National Immunization Survey-Child 2012-2018, United States
The proportion of children that received no vaccinations by age 24 months increased slightly across birth years 2011 through 2016, with an estimated change per year of 0.09 percentage points.

Abbreviations: CI = confidence interval

* Kaplan-Meier techniques are used to calculate estimates by age 24 months.

Children born in 2011 are included in survey years 2012, 2013, and 2014; children born in 2012 are included in survey years 2013, 2014, and 2015; children born in 2013 are included in survey years 2014, 2015, and 2016, children born in 2014 are included in survey years 2015, 2016, and 2017; children born in 2015 are included in survey years 2016, 2017, and 2018; children born in 2016 are included in survey years 2017 and 2018 (data from survey year 2019 are not yet available). Estimated linear relationship between year of birth and vaccination status, based on weighted linear regression analysis using the inverse of the estimated variance of each point estimate to construct the weights. Observed percent unvaccinated (95% confidence interval): 2011 0.9 (0.7-1.1); 2012 1.1 (0.8-1.4); 2013 1.1 (0.8-1.4), 2014 1.2 (1.0-1.5); 2015 1.3 (1.1-1.6); 2016 1.2 (0.9-1.6). Estimated percentage point change per year: 0.09 (0.04-0.14).